文献类型：期刊文献

英文题名：Evolving role of biomarkers beyond prostate-specific antigen in refining prostate cancer screening: From blood-based tests to urinary and genetic markers (Review)

作者：Li, Luxi[1,2];Zhang, Linyue[1,2];Li, Zehong[1,2];Chai, Keqiang[1,2];Ren, Weidong[3]

第一作者：Li, Luxi

通信作者：Chai, KQ[1];Ren, WD[2]

机构：[1]Gansu Univ Chinese Med, Peoples Hosp Baiyin City 1, Affiliated Hosp 3, Urol Ctr, 222 Silong Rd, Baiyin 730900, Gansu, Peoples R China;[2]Gansu Univ Chinese Med, Peoples Hosp Baiyin City 1, Affiliated Hosp 3, Dept Urol, Baiyin 730900, Gansu, Peoples R China;[3]Gansu Univ Chinese Med, Peoples Hosp Baiyin City 1, Affiliated Hosp 3, Hlth Management Ctr, 222 Silong Rd, Baiyin 730900, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Peoples Hosp Baiyin City 1, Affiliated Hosp 3, Urol Ctr, 222 Silong Rd, Baiyin 730900, Gansu, Peoples R China;[2]corresponding author), Gansu Univ Chinese Med, Peoples Hosp Baiyin City 1, Affiliated Hosp 3, Hlth Management Ctr, 222 Silong Rd, Baiyin 730900, Gansu, Peoples R China.|[10735]甘肃中医药大学;

年份：2026

卷号：34

期号：3

外文期刊名：MOLECULAR MEDICINE REPORTS

收录：;Scopus(收录号：2-s2.0-105045211078);WOS:【SCI-EXPANDED(收录号:WOS:001817091400001)】；

基金：Not applicable.

语种：英文

外文关键词：PCa; screening; biomarkers; prostate-specific antigen isoforms; liquid biopsy; urinary biomarkers; genetic markers

摘要：Prostate-specific antigen (PSA) screening reduces prostate cancer (PCa) mortality but is limited by overdiagnosis and poor specificity for clinically significant disease. These limitations drive the need for more accurate biomarkers to distinguish aggressive cancers from indolent lesions. The present review examined advanced blood-based markers, including PSA isoforms, liquid biopsy components and the Prostate Health Index; urinary biomarkers, such as PCa antigen 3, transmembrane protease serine 2-v-ets erythroblastosis virus E26 oncogene homolog fusion and the MyProstateScore 2.0 panel; and genetic markers ranging from high-penetrance germline mutations to polygenic risk scores. It further explored the integration of these biomarkers with multiparametric MRI, risk-calculator models and health-economic evaluations to optimize screening pathways. Future directions involve multi-omic profiling, artificial intelligence and novel biosensing technologies. The present review aimed to provide a comprehensive and balanced perspective on emerging biomarkers that are reshaping personalized PCa screening.